Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Dow, S&P 500 manage record closing highs ; Nasdaq falls in volatile session
4/10/2025
Gold stocks beat AI-led chip rally with 135% gain in 2025
4/10/2025
M-cap share of defensives hits lowest level since 2011 : ICICI Securities
4/10/2025
Will stock-specific trading continue to drive market gains ?
4/10/2025
Robust consumption bulwark against external shocks : FM Sitharaman
4/10/2025
Soaring prices stall Dussehra gold rush, volume down 25% this year
4/10/2025
